scp776 / Silver Creek Pharma - LARVOL DELTA

ARPEGGIO PHASE 2 RANDOMIZED DOSE SELECTION TRIAL OF NOVEL CEREBROPROTECTANT SCP776 IN EVT TREATED AIS PATIENTS (WSC 2025) - "The last study assessment will be completed in 09/2025 and data-cleaning is underway.ConclusionsThis two-part Phase 2 study establishes safety and explores early efficacy signals for scp776 as a cerebroprotective adjunctive to EVT. Pending results will guide dose selection, future pivotal drug development, and the potential to improve outcomes in large vessel occlusion stroke."

Clinical • Late-breaking abstract • P2 data • Cardiovascular • Ischemic stroke • Reperfusion Injury • IGF1

Silver Creek Pharmaceuticals Receives FDA Fast Track Designation for Scp776 in Acute Ischemic Stroke (GlobeNewswire) - "Novel mechanism of action reverses and prevents death of injured cells. Phase II ARPEGGIO trial fully enrolled. Topline results to be presented at the World Stroke Congress, October 23, 2025."

Enrollment status • Fast track • P2 data • Ischemic stroke

Arpeggio: Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: Silver Creek Pharmaceuticals | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2025 ➔ Jan 2026 | Trial primary completion date: Jun 2025 ➔ Oct 2025

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

Arpeggio: Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Silver Creek Pharmaceuticals | N=80 ➔ 120 | Trial completion date: Feb 2025 ➔ Oct 2025 | Trial primary completion date: Nov 2024 ➔ Jun 2025

Enrollment change • Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

Scp776, A Novel IGF-1 Fusion Protein for Acute Therapy to Promote Escape From Apoptosis in Tissues Affected by Ischemic Injury: 2 Randomized Placebo-Controlled Phase 1 Studies in Healthy Adults. (PubMed, Clin Pharmacol Drug Dev) - "Adaptive dextrose infusions maintained normal blood glucose levels with occasional mild hypoglycemic events. These results informed scp776 dose selection and the design of blood glucose monitoring protocols for phase 2 studies."

Journal • P1 data • Cardiovascular • Hypoglycemia • Ischemic stroke • Myocardial Infarction • IGF1

Arpeggio: Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Silver Creek Pharmaceuticals | Trial completion date: Jun 2024 ➔ Feb 2025 | Trial primary completion date: Mar 2024 ➔ Nov 2024

Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

A Pilot, Safety, Efficacy and Feasibility Double-Blind Randomised Controlled Trial of Scp776 for Neuroprotection in Comatose Adults Resuscitated After Out-of-Hospital Cardiac Arrest (ANZCTR) - P2 | N=40 | Not yet recruiting | Sponsor: Austin Hospital

New P2 trial • Cardiovascular • NEFL

IMPLEMENTATION OF AN ADAPTIVE BLOOD GLUCOSE MANAGEMENT PLAN FOR A NOVEL, TARGETED IGF-1 FUSION PROTEIN IN A PHASE 1 STUDY IN HEALTHY ADULTS (WSC 2023) - "The strategy of low dose dextrose supplementation adjusted incrementally per bedside glucose monitoring successfully maintained serum glucose levels throughout multiple administrations of scp776."

Clinical • P1 data • Cardiovascular • Hypoglycemia • Ischemic stroke • IGF1

ARPEGGIO: Cerebroprotective Effect And Safety Of Scp776, An Igf-1 Fusion Protein Targeted To Damaged Tissues, In Large Vessel Ischemic Stroke Patients Undergoing Thrombectomy Without Thrombolysis (ISC 2023) - P2 | "Subjects are monitored through Days 30 and 90 for safety and functional outcomes. Principal Investigator: Lakhmir Chawla, MD Sponsor: Silver Creek Pharmaceuticals Status: Study initiated in October 2022."

Clinical • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Immunology • Ischemic stroke • Reperfusion Injury • IGF1

Arpeggio: Phase 2 Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Silver Creek Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Ischemic stroke

Arpeggio: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Silver Creek Pharmaceuticals

New P2 trial • Cardiovascular • Ischemic stroke